Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 73
States / cities: Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Asthma
Interventions: Placebo DPI, ELLIPTA DPI, Ease of use questionnaires; Drug · Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 15
States / cities: Little Rock, Arkansas • Huntington Beach, California • Napa, California + 12 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antioxidant supplement, Diabetes treatment, Regular Insulin; Dietary Supplement · Other · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Asthma
Interventions: BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 70
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 66 more

Conditions: Tobacco Abuse Smoke
Interventions: Fluticasone, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 87
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 69
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions: arformoterol tartrate inhalation solution, Salmeterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 65
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Asthma
Interventions: E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Costa Mesa, California • Orange, California • Stockton, California + 5 more

Conditions: Exercise-induced Bronchospasm
Interventions: Levalbuterol tartrate HFA MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Denver, Colorado • Burke, Virginia

Conditions: Asthma
Interventions: Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 14
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more

Conditions: Asthma
Interventions: levalbuterol tartrate MDI, racemic albuterol MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 63
States / cities: Homewood, Alabama • Mobile, Alabama • Corona, California + 55 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Conditions: Asthma
Interventions: BI 671800, Placebo, Montelukast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more

Conditions: Asthma
Interventions: Placebo, Fluticasone propionate, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 37
States / cities: Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Search by objective public record fields.

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Evaluation of Efficacy and Safety of E004 in Children With Asthma

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD